Biostatistics and bioinformatics support for transplant and MRD decision-making
Core 5 - Biostatistics and Bioinformatics Core
Using advanced data analysis, this project helps doctors compare high-dose chemotherapy with stem cell transplant against more induction chemotherapy for patients with measurable residual disease in blood cancers.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11179335 on NIH RePORTER |
What this research studies
From a patient perspective, this project organizes and analyzes clinical, genomic, and epigenomic data to help guide treatment choices after initial therapy. It supports a randomized Phase III approach that compares high-dose therapy plus autologous stem cell transplant versus additional induction cycles for patients who are MRD negative, and single versus tandem transplants for patients who remain MRD positive. The core manages data quality, formatting, and integrated statistical analysis so clinicians can use MRD results and molecular findings to personalize care. By combining clinical outcomes with deep molecular data, the team aims to identify which patients benefit most from transplant strategies.
Who could benefit from this research
Good fit: Ideal candidates are people with a blood cancer who have finished induction therapy, have measurable residual disease (MRD) testing results, and are being considered for autologous stem cell transplant or additional chemotherapy.
Not a fit: People without MRD testing, those with solid tumors, or patients who are not candidates for autologous stem cell transplant are unlikely to benefit directly from this project.
Why it matters
Potential benefit: If successful, this work could help patients get the right intensity of treatment based on MRD and molecular data, improving outcomes while avoiding unnecessary procedures.
How similar studies have performed: Previous studies have shown that achieving MRD negativity is linked to longer progression-free and overall survival, and prior trials have demonstrated a progression-free survival benefit from high-dose chemotherapy followed by autologous transplant.
Where this research is happening
Boston, United States
- Dana-Farber Cancer Inst — Boston, United States (Active)
Researchers
- Principal investigator: Parmigiani, Giovanni Luigi — Dana-Farber Cancer Inst
- Study coordinator: Parmigiani, Giovanni Luigi
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.